As pharmaceutical products become more complex, technical operations is no longer a late-stage function. It is becoming a strategic bridge between science, regulatory planning and commercial delivery.
That was the central message from Rosario Lobrutto, PhD, MBA, MS, Vice President and Global Head of Technical Operations at Ironwood Pharmaceuticals, who discussed how companies can better prepare complex therapies for successful development, scale-up and launch.
At Ironwood, Lobrutto oversees a broad technical operations organisation spanning CMC, device, external manufacturing, supply chain and technical oversight of manufacturing partners. Because the company operates through an external network, a major part of the role involves building strong strategic relationships with CDMOs and suppliers.
For Lobrutto, global technical operations is about ensuring that development and commercial strategy can be reliably translated into products that can be manufactured, supplied and delivered to patients.
One of the biggest priorities is preparing for commercialisation long before clinical success. A process that works at clinical scale may not be ready for technology transfer or commercial manufacturing. Companies need to understand critical process parameters, critical quality attributes, analytical strategies, supply risks and even geopolitical risks well ahead of launch.
For complex products, this means thinking early about capacity, redundancy, raw material availability and whether the CDMO network can support both launch and future growth.
CMC strategy, manufacturing readiness and regulatory planning also need to evolve together as products move through development. Early programmes may prioritise speed and learning, but later-stage development demands process understanding, control, reproducibility, validation and commercial readiness.
By Phase III, Lobrutto argued, companies should already be thinking like commercial organisations: locking down processes and specifications, understanding comparability, establishing control strategies, securing capacity and ensuring regulatory filings accurately reflect how the product will be manufactured commercially.
Scaling remains one of the most common pressure points. Across small molecules, peptides, proteins and injectables, companies often assume processes will scale linearly — but mixing, mass transfer, purification, filtration, lyophilisation and formulation behaviour can all change significantly at scale. Analytical methods, raw material variability and supply chain resilience can also determine whether a programme is truly commercially viable.
Looking ahead, Lobrutto sees major opportunities in AI, advanced process modelling, continuous manufacturing, automation and advanced analytics. AI, in particular, could help technical operations move from reacting to manufacturing problems to predicting them, whether in process optimisation, formulation development, regulatory writing, supply forecasting or risk detection.
However, technology alone will not be enough. In a virtual operating model, the relationship between sponsors and CDMOs must become less transactional and more strategic. The strongest partnerships, Lobrutto noted, increasingly operate like extensions of the sponsor’s own organisation, built on shared technical knowledge, transparency and long-term capacity planning.
Ultimately, the future of technical operations will be more predictive, more resilient and more closely integrated with development and commercial strategy.
